Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.

Protein kinase C-β distinctly regulates blood-brain barrier-forming capacity of Brain Microvascular endothelial cells and outgrowth endothelial cells

Open access
Kadir, Rais Reskiawan A., Alwjwaj, Mansour, Bayraktutan, Ulvi · 2022 · Metabolic Brain Disease

Abstract

Outgrowth endothelial cells (OECs) provide an endogenous repair mechanism and thus maintain endothelial barrier integrity. As inhibition of protein kinase C-β (PKC-β) activity has been shown to attenuate endothelial damage in various pathological conditions including hyperglycaemia and ischaemic injury, the present study comparatively assessed the effect of LY333531, a PKC-β inhibitor, on the cerebral barrier integrity formed by OECs or human brain microvascular endothelial cells (HBMECs). To this end, an in vitro model of human BBB established by co-culture of astrocytes and pericytes with either OECs or HBMECs was exposed to 4 h of oxygen-glucose deprivation with/out LY333531 (0.05 µM). The inhibition of PKC-β protected the integrity and function of the BBB formed by HBMECs, as evidenced by increases in transendothelial electrical resistance and decreases in sodium fluorescein flux. It also attenuated ischaemia-evoked actin cytoskeleton remodelling, oxidative stress, and apoptosis in HBMECs. In contrast, treatments with LY333531 exacerbated the deleterious effect of ischaemia on the integrity and function of BBB formed by OECs while augmenting the levels of oxidative stress, apoptosis, and cytoskeletal reorganisation in OECs. Interestingly, the magnitude of damage in all aforementioned parameters, notably oxidative stress, was lower with low dose of LY333531 (0.01 µM). It is therefore possible that the therapeutic concentration of LY333531 (0.05 µM) may neutralise the activity of NADPH oxidase and thus trigger a negative feedback mechanism which in turn exacerbate the detrimental effects of ischaemic injury. In conclusion, targeting PKC-β signalling pathway in ischaemic settings requires close attention while using OECs as cellular therapeutic.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s11011-022-01041-1

Cites

47 of 47 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Representative images for HBMEC and OEC morphology, tube formation, and endothelial characterisation. (A) Both HBMECs and OECs show a cobblestone morphology, well-established tubules structure on matrigel, and positive staining with FITC-conjugated ulex europaeus agglutinin-1 (FITC-UEA-1) and Dil-labelled acetylated-low density lipoprotein (Dil-Ac-LDL). Quantitative analyses of the number and length of tubule networks (B) as well as the fluorescence intensity of FITC-UEA-1 and Dil-Ac-LDL signal (C) show similar readings for both cells. Scale bar 100 μm. NS: not significant
Fig. 1 Representative images for HBMEC and OEC morphology, tube formation, and endothelial characterisation. (A) Both HBMECs and OECs show a cobblestone morphology, well-established tubules structure on matrigel, and positive staining with FITC-conjugated ulex europaeus agglutinin-1 (FITC-UEA-1) and Dil-labelled acetylated-low density lipoprotein (Dil-Ac-LDL). Quantitative analyses of the number and length of tubule networks (B) as well as the fluorescence intensity of FITC-UEA-1 and Dil-Ac-LDL signal (C) show similar readings for both cells. Scale bar 100 μm. NS: not significantCC BY · PubMed Central
Fig. 2 The schematic diagram of an in vitro model of human BBB consisted of HBMECs or OECs in the presence of astrocytes and pericytes (A). The inhibition of PKC-β (LY333531, 0.05 µM) protected BBB integrity (B) and function (C), as observed by the increases in TEER value and decreases in the flux of permeability marker, sodium fluorescein. Although OECs form equally tight and functional BBB (as indicated by the blue line), the inhibition of PKC-β (LY333531, 0.05 µM) exacerbates ischaemia-evoked damage in BBB established with OECs. *p < 0.05 versus control, #p < 0.05 versus OGD
Fig. 2 The schematic diagram of an in vitro model of human BBB consisted of HBMECs or OECs in the presence of astrocytes and pericytes (A). The inhibition of PKC-β (LY333531, 0.05 µM) protected BBB integrity (B) and function (C), as observed by the increases in TEER value and decreases in the flux of permeability marker, sodium fluorescein. Although OECs form equally tight and functional BBB (as indicated by the blue line), the inhibition of PKC-β (LY333531, 0.05 µM) exacerbates ischaemia-evoked damage in BBB established with OECs. *p < 0.05 versus control, #p < 0.05 versus OGDCC BY · PubMed Central
Fig. 3 Representative images for actin cytoskeleton in HBMECs and OECs subjected to ischaemic injury in the presence or absence of LY333531. (A) While the presence of LY333531 (0.05 µM) diminished actin stress fibre formation evoked by OGD in HBMECs as indicated by white arrow, it produced the opposite effects in OECs. (B) The number of stress fibres formation in both cells. *p < 0.05 versus control, #p < 0.05 versus OGD. Scale bar: 20 μm
Fig. 3 Representative images for actin cytoskeleton in HBMECs and OECs subjected to ischaemic injury in the presence or absence of LY333531. (A) While the presence of LY333531 (0.05 µM) diminished actin stress fibre formation evoked by OGD in HBMECs as indicated by white arrow, it produced the opposite effects in OECs. (B) The number of stress fibres formation in both cells. *p < 0.05 versus control, #p < 0.05 versus OGD. Scale bar: 20 μmCC BY · PubMed Central
Fig. 4 The effect of PKC-β inhibition on NADPH oxidase activity (A), superoxide anion release (B), and total anti-oxidant capacity (C) in HBMEC and OECs subjected to experimental ischaemic injury. While the inhibition of PKC-β using LY333531 (0.05 µM) decreased NADPH oxidase activity and superoxide anion level in HBMEC, it further augmented both parameters in OECs. The presence of LY333531 (0.05 µM) during OGD increased total anti-oxidant capacity in HBMECs but not in OECs. *p < 0.05 versus control, #p < 0.05 versus OGD
Fig. 4 The effect of PKC-β inhibition on NADPH oxidase activity (A), superoxide anion release (B), and total anti-oxidant capacity (C) in HBMEC and OECs subjected to experimental ischaemic injury. While the inhibition of PKC-β using LY333531 (0.05 µM) decreased NADPH oxidase activity and superoxide anion level in HBMEC, it further augmented both parameters in OECs. The presence of LY333531 (0.05 µM) during OGD increased total anti-oxidant capacity in HBMECs but not in OECs. *p < 0.05 versus control, #p < 0.05 versus OGDCC BY · PubMed Central
Fig. 5 The effects of PKC-β inhibition on cellular apoptosis and viability rates. Representative Hoechst staining showing increases in apoptosis of HBMEC and OECs (indicated by white arrows) exposed to OGD (A). Data graphs showing the quantification of apoptotic cells (B). In HBMECs, treatment with LY333531 (0.05 µM) decreased the impact of OGD on caspase 3/7 activity (C) and thus enhanced their viability (D), it produced the opposite effects in OECs. *p < 0.05 versus control, #p < 0.05 versus OGD. Scale bar: 100 μm
Fig. 5 The effects of PKC-β inhibition on cellular apoptosis and viability rates. Representative Hoechst staining showing increases in apoptosis of HBMEC and OECs (indicated by white arrows) exposed to OGD (A). Data graphs showing the quantification of apoptotic cells (B). In HBMECs, treatment with LY333531 (0.05 µM) decreased the impact of OGD on caspase 3/7 activity (C) and thus enhanced their viability (D), it produced the opposite effects in OECs. *p < 0.05 versus control, #p < 0.05 versus OGD. Scale bar: 100 μmCC BY · PubMed Central
Fig. 6 Comparative analyses of the effects of therapeutic and low doses of LY333531 on key elements related oxidative stress and cellular viability in OECs. Exposure to a lower dose of (0.01 µM) LY333531 significantly reduced NADPH oxidase activity (A), superoxide anion production (B), and caspase 3/7 activity (C), and increased rate of survival (D) compared to their counterparts treated with 0.05 µM LY333531. *p < 0.05 versus control, #p < 0.05 versus 0.05 µM dose
Fig. 6 Comparative analyses of the effects of therapeutic and low doses of LY333531 on key elements related oxidative stress and cellular viability in OECs. Exposure to a lower dose of (0.01 µM) LY333531 significantly reduced NADPH oxidase activity (A), superoxide anion production (B), and caspase 3/7 activity (C), and increased rate of survival (D) compared to their counterparts treated with 0.05 µM LY333531. *p < 0.05 versus control, #p < 0.05 versus 0.05 µM doseCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 47 references

Cited by

See all 18

Metadata

Authors
Kadir, R. R. A., Alwjwaj, M., & Bayraktutan, U.
Affiliations
University of Nottingham (GB)
Corresponding author
Bayraktutan, Ulvi
Venue
Metabolic Brain Disease
Published
2022-06-28
Volume
37
Issue
6
Pages
1815-1827
ISSN
  • 0885-7490 (ISSN-L)
  • 1573-7365
OpenAlex
W4283639743
Cited by
17
References
47
Citations by year
2026: 2 · 2025: 5 · 2024: 4 · 2023: 5 · 2022: 1
FWCI
1.32
Type
journal article
Language
en
Open access
Licence
Locations
  • Metabolic Brain Disease (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Repository@Nottingham (University of Nottingham) (publishedVersion, cc-by)
  • Repository@Nottingham (University of Nottingham) (submittedVersion, cc-by)
Funders
  • Dunhill Medical Trust (R459/0216)
  • Indonesian Endowment Fund for Education, Ministry of Finance, Republic of Indonesia (201712220412095)
Topics
  • Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
  • Health Sciences › Medicine › Clinical Neurology › Acute Ischemic Stroke Management
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Extracellular vesicles in disease
Keywords
protein kinase C beta, ruboxistaurin, blood-brain barrier, brain microvascular endothelial cells, outgrowth endothelial cells, cerebral ischemia, oxygen-glucose deprivation, oxidative stress, apoptosis, actin cytoskeleton remodeling, NADPH oxidase, endothelial repair, transendothelial electrical resistance
MeSH terms
Blood-Brain Barrier, Brain, Cells, Cultured, Humans, Ischemia, Endothelial Cells, Protein Kinase C beta

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Protein kinase C-β distinctly regulates blood-brain barrier-forming capacity of Brain Microvascular endothelial cells and outgrowth endothelial cells. https://app.cochat.ai/papers/10.1007/s11011-022-01041-1
The paper
Kadir, R. R. A., Alwjwaj, M., & Bayraktutan, U. (2022). Protein kinase C-β distinctly regulates blood-brain barrier-forming capacity of Brain Microvascular endothelial cells and outgrowth endothelial cells. Metabolic Brain Disease. https://doi.org/10.1007/s11011-022-01041-1

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.